Unlike earlier treatments that focused on a single pathway, retatrutide is engineered to interact with several hormonal receptors involved in appetite regulation, insulin sensitivity and energy expenditure
The compound is frequently referred to as a triple-hormone-receptor agonist retatrutide because it simultaneously targets: GLP-1 receptor pathways Glucagon receptor pathways Glucose-dependent insulinotropic polypeptide receptor pathways This triple agonist mechanism differentiates retatrutide from earlier GLP-1 receptor agonist compounds and other research peptides currently studied for obesity and metabolic dysfunction
"While these medications are producing excellent results in most people, it is possible that some people actually don't eat enough," says Dr
More than 30 million Americans are using some form of weight loss drug, often with significant results
The leaner you are, the better your body shuttles nutrients toward muscle rather than fat storage
Ultimately, McCoy hopes retatrutide will soon add to a growing tool kit to tackle type 2 diabetes and obesity
